Regeneron Signs a Research and Option to License Agreement with Vyriad for Oncolytic Virus-Based Therapies

Regeneron and Sanofi Reports Results of Praluent (alirocumab) in ODYSSEY OUTCOMES study in Patients with MACE events, Presented at AHA 2018


  • Vyriad to receive upfront, development and commercial milestone payments based on certain achievements and royalties on sales of products. Regeneron to get an exclusive option to license Vyriad’s Voyager-V1 plus other products and will make equity investment in Vyriad
  • The agreement also includes a P-II clinical study assessing Regeneron’s Libtayo (cemiplimab-rwlc) + Vyriad’s oncolytic virus Voyager-V1 in multiple types of cancer, including melanoma, lung, liver and endometrial cancers. Additionally, the companies will enter into a five-year research collaboration to design and develop Vesicular Stomatitis Virus (VSV)-based oncolytic virus therapies utilizing Regeneron’s VelociSuite technologies
  • Voyager-V1 is an oncolytic virus designed to enhance safety, efficacy, and traceability with the inclusion of interferon-beta gene and is also being evaluated in P-I/II study for mCRC, endometrial cancer, NSCLC, SCC of the head and neck and various blood cancers. Regeneron’s Libtayo is a mAb targeting immune checkpoint receptor PD-1 developed in collaboration with Sanofi

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance